Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

IMMUNOTHERAPY

Signatures IMPRES and might turn the TIDE in predicting responses

Nature Reviews Clinical Oncology volume 15, page 654 (2018)Cite this article

Subjects

Access through your institution
Buy or subscribe

Immune-checkpoint inhibitors (ICIs) can provide major therapeutic benefits, but most patients do not respond to these agents. Now, two studies published in Nature Medicine highlight the potential of tumour transcriptome profiling to improve the allocation of ICIs.

In one study, a computational tumour immune dysfunction and exclusion (TIDE) framework was developed using data from >33,000 human tumour specimens by testing the effects of interactions among the candidate genes with either cytotoxic T cells or immunosuppressive cell signatures on the risk of death. Thus, “TIDE differs from existing biomarkers by providing signatures of both T cell dysfunction in immunologically ‘hot’ tumours and T cell exclusion in ‘cold’ tumours,” explains Shirley Liu. “Instead of deriving response biomarkers from immunotherapy cohorts, we derived these signatures from publicly available treatment-naive tumour data sets with transcriptome and patient survival information,” Liu adds. “Such data have been used extensively to examine the impact of a particular gene or pathway on patient survival; our approach now enables investigators to determine whether these relationships correlate with immune function,” says co-author Kai Wucherpfennig.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original articles

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Signatures IMPRES and might turn the TIDE in predicting responses. Nat Rev Clin Oncol 15, 654 (2018). https://doi.org/10.1038/s41571-018-0088-x

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-018-0088-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer